Reckitt Benckiser Group Plc. (RBGLY) Stock Price & How to Invest

Reckitt Benckiser Group plc sells everyday health and cleaning products in close to every country. It now reports two businesses. Core Reckitt holds four categories: Self Care (Mucinex, Nurofen, Strepsils, Gaviscon), Germ Protection (Dettol and Lysol), Household Care (Finish dishwasher products, Vanish stain removers and Harpic toilet cleaners) and Intimate Wellness (Durex). Mead Johnson Nutrition, which sells Enfamil and Nutramigen infant formula, sits outside the core and is treated as non-core while the company considers all options for it. In 2025 group net revenue was ~£14.2 billion, and like-for-like growth excluding Essential Home was 5.0%. In the March 2026 quarter, Core Reckitt's ~£2.6 billion of net revenue split as ~£1.09 billion from emerging markets, ~£873 million from Europe and ~£638 million from North America, and Mead Johnson added ~£531 million.

The modern company dates from the 1999 merger of Britain's Reckitt & Colman with Benckiser of the Netherlands. It grew through acquisitions: Boots Healthcare International in 2006 (Nurofen, Strepsils), Adams Respiratory in 2008 (Mucinex), SSL International in 2010 (Durex) and Mead Johnson in 2017 for ~$17.9 billion including debt. That last deal turned out badly, with write-downs and now product-liability suits over premature-infant formula. The group shortened its trading name to Reckitt in 2021. In 2024 it said it would exit Essential Home, and the sale of Air Wick, Cillit Bang and other home brands to Advent International for ~£2.2 billion completed on December 31, 2025, with Reckitt keeping a 30% stake in the buyer.

Reckitt is headquartered in Slough, England, and its shares trade on the London Stock Exchange under the ticker RKT as a FTSE 100 member. It has no controlling shareholder. Kris Licht has been chief executive since late 2023 and Shannon Eisenhardt is chief financial officer. RBGLY is a sponsored ADR quoted in US dollars on the OTC Pink tier. Reckitt's market value against the RBGLY price works out to roughly five ADRs per London ordinary share. Dividends are declared in pence and paid to ADR holders in dollars after currency conversion and depositary fees; the UK does not withhold tax on dividends.

The investment picture is a company trying to prove a simpler model. Core Reckitt grew 5.2% like-for-like in 2025, above its 4% to 5% target, with emerging markets up 14.6%. Momentum then faded: Core growth was 1.3% in the March 2026 quarter after a weak cold and flu season, and 2.7% for the first half, although the June quarter improved to 4.2%. Adjusted operating margin was 24.9% for 2025, and management expects the 2026 margin to be weighted to the second half. Shareholder returns are large: a £1.6 billion special dividend paid in February 2026 from the Essential Home proceeds, a £1 billion buyback that began in July 2025, a further £500 million buyback announced in July 2026, and an ordinary dividend that rose 5% for 2025 to 212.2p.

Litigation is the risk that sets Reckitt apart from its peers. Mead Johnson and Abbott face more than 2,000 lawsuits in the US alleging that formula for premature babies is linked to necrotizing enterocolitis, a serious bowel disease. Mead Johnson has recently won: a federal bellwether jury found for it, a St. Louis jury cleared it in July 2026, and an Illinois appeals court threw out a $60 million verdict from March 2024 and sent the case back for retrial. Abbott has fared worse, including a $495 million verdict upheld on appeal in Missouri, which shows how large single awards can be. Reckitt denies that its products cause NEC, but more trials are ahead and a run of losses could cost far more than the reserves investors assume. Operating risks are also real. Core growth slowed to 1.3% in the March 2026 quarter, Europe is shrinking, Household Care fell 7.6%, and the cold and flu season can swing Self Care in any quarter. Russia sanctions changes and the Middle East conflict hit emerging markets in early 2026, and the transfer of the Russian business is still in progress. Higher oil prices could add ~£130 million to £150 million to input costs, and a Mead Johnson sale may fetch less than hoped while the lawsuits remain open. For US holders, RBGLY's dollar price moves with sterling, dividends are reduced by depositary fees, and OTC volume can be lighter than the London line.

4 analysts publish price targets on RBGLY, averaging $16.20 against a $13.71 price as of October 2026, or +18.2%. The published targets run from $14.37 to $18.66, a narrow spread, and the ratings split 2 buy, 2 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full RBGLY forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Reckitt Benckiser Group Plc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Emerging markets as the growth engine. Emerging markets are now Core Reckitt's largest region, at ~£1.09 billion of net revenue in the March 2026 quarter, and they grew 14.6% like-for-like in 2025 with double-digit gains in China and India, and also in Indonesia and Colombia. The most optimistic published target, $18.66, assumes this works close to its best case.

The case against. Litigation is the risk that sets Reckitt apart from its peers. The most pessimistic target, $14.37, is roughly what RBGLY is worth if this bites instead.

Read the full bull and bear case on RBGLY, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Reckitt Benckiser Group Plc.'s investor relations page or your broker.

• Net revenue (FY 2025, group): ~£14.2 billion
• Adjusted operating profit (FY 2025): ~£3.54 billion, 24.9% margin
• Net revenue (H1 2026): ~£6.41 billion
• Adjusted diluted EPS (H1 2026): 152.1p, down 9.7%
• Ordinary dividend (FY 2025): 212.2p per share
• Market cap (RBGLY quote): ~$43 billion

Reported revenue is falling because Essential Home left the group on December 31, 2025, which is why first-half 2026 net revenue (~£6.41 billion) came in below the prior year's ~£6.98 billion even as like-for-like sales grew 2.6%. Yahoo Finance shows RBGLY at ~11.5x trailing earnings, a figure flattered by disposal gains, and ~14x forward earnings, which is a lower multiple than many large consumer-staples peers. The forward yield of ~4.2% rests on a dividend that the company raised 5% for 2025 and again at the 2026 interim. The discount reflects slower growth in developed markets and the open-ended NEC litigation.

Other names that sit close to RBGLY: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get RBGLY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so RBGLY sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where RBGLY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

RBGLY is a high-yield bet on a slimmed-down consumer health and hygiene company getting back to 4% to 5% growth while it decides what to do with Mead Johnson and its infant-formula lawsuits.

Whether RBGLY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RBGLY a buy or a sell?, and where the stock could go from here in the RBGLY stock forecast.

For income investors, whether RBGLY pays a dividend and how the payout looks is covered in does RBGLY pay a dividend? And to weigh RBGLY against a peer, read the full side-by-side comparisons: RBGLY vs PG and RBGLY vs UL.